Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Did Ocera Therapeutics Inc. (OCRX) Rebound in Thursday’s After-market Hours

While Ocera Therapeutics Inc. (NASDAQ:OCRX) closed down 0.83% on Thursday, it rebounded by 36.13% in after-market hours to $1.62, after revealing positive results to its pre-clinical study of the ornithine phenylacetate (OCR-002) against high fat and high cholesterol.

The study proved that OCR-002 substantially reduced liver/body weight ratio, hepatic lipid content, and hepatic collagen, among others.

The study investigated the effect of OCR-002 in a non-alcoholic fatty liver disease (NAFLD) rat model in which animals were fed a High Fat and High Cholesterol (HFHC) diet for up to 16 weeks. Compared to normal rats, NAFLD rats showed a significant increase in ammonia (p<0.05), as well as increased blood levels of cholesterol, ALT and AST. The NAFLD rats treated with OCR-002 showed significant reduction in the progression of fibrosis compared to untreated NAFLD rats, Ocera Therapeutics Inc. (NASDAQ:OCRX) said.

“The data provide further proof that ammonia is more than just a neurotoxin and establishes ammonia as a therapeutic target for the prevention of progression of non-alcoholic fatty liver disease. As OCR-002 is already in advanced stages of clinical development, these data can readily be translated into real benefits for patients with appropriate clinical trials,” said Professor Rajiv Jalan, M.B.B.S, M.D. Ph.D.

 

Looker_Studio/Shutterstock.com

Looker_Studio/Shutterstock.com

What Does The Smart Money Sentiment Say?

The Smart Money remained stable of its view on Ocera Therapeutics Inc. (NASDAQ:OCRX) , from Q3 to Q4 in 2016. Out of 742 hedge funds that we track at Insider Monkey, 9 funds held on to their positions, quarter over quarter. Looking more closely at the pool, Anders Hove and Bong Koh of VHCP Management increased its holdings by 7%, to cover 912,050 shares valued at $1.9 million by the end of Q4.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

The Bottom Line

Ocera Therapeutics Inc. (NASDAQ:OCRX) shares rose in weak trading during after-market hours following positive results to its pre-clinical study of the OCR-002 to reduce fats and cholesterol. For lighter reading, check out the 11 fattest countries in the world.

Follow Ocera Therapeutics Inc. (NASDAQ:OCRX)
Trade (NASDAQ:OCRX) Now!
Loading...